Short-and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue

Nutrition and Diabetes

Volumn 1, Issue 1, 2011, Pages

  Gathercole, L L ^a   Morgan, S A ^a   Bujalska, I J ^a   Stewart, P M ^a   Tomlinson, J W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

adipocyte; cortisol; glucocorticoids; insulin signalling; obesity

Indexed keywords

DEXAMETHASONE; INSULIN; MESSENGER RNA;

ABDOMINAL SUBCUTANEOUS FAT; ACUTE DRUG ADMINISTRATION; ADIPOCYTE; ADIPOGENESIS; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EXPOSURE; GENE EXPRESSION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION;

EID: 84884211422     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2010.3     Document Type: Article

References (21)

1. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93/2: 105-111.
2. Larsson H, Ahren B. Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J Clin Endocrinol Metab 1996; 81/12: 4428-4432.
3. Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J Clin Endocrinol Metab 2007; 92/11: 4332-4339.
4. Tomlinson JJ, Boudreau A,Wu D, Abdou SH, Carrigan A, Gagnon A et al. Insulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factors. Mol Endocrinol 2010; 24/1: 104-113.
5. Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ et al. 11{beta}-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009; 58: 2506-2515.
6. Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 1993; 92/4: 2065-2072.
7. Nosadini R, Del PS, Tiengo A, Valerio A, Muggeo M, Opocher G et al. Insulin resistance in Cushing's syndrome. J Clin Endocrinol Metab 1983; 57/3: 529-536.
8. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2001; 107/2: 181-189.
9. Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, Fanjul AN et al. A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 2008; 197/2: 297-307.
10. Hauner H, Schmid P, Pfeiffer EF. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab 1987; 64/4: 832-835.
11. Lundgren M, Buren J, Lindgren P, Myrnas T, Ruge T, Eriksson JW. Sex-and depot-specific lipolysis regulation in human adipocytes: interplay between adrenergic stimulation and glucocorticoids. Horm Metab Res 2008; 40: 854-860.
12. Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW. Glucocorticoids down-regulate glucose uptake capacity and insulinsignaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 2004; 89/6: 2989-2997.
13. Buren J, Liu HX, Jensen J, Eriksson JW. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol 2002; 146/3: 419-429.
14. Buren J, Lai YC, Lundgren M, Eriksson JW, Jensen J. Insulin action and signalling in fat and muscle from dexamethasone-treated rats. Arch Biochem Biophys 2008; 474/1: 91-101.
15. Tonolo G, Fraser R, Connell JM, Kenyon CJ. Chronic low-dose infusions of dexamethasone in rats: effects on blood pressure, body weight and plasma atrial natriuretic peptide. J Hypertens 1988; 6/1: 25-31.
16. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 2008; 295/4: E785-E797.
17. Bujalska IJ, Quinkler M, Tomlinson JW, Montague CT, Smith DM, Stewart PM. Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J Mol Endocrinol 2006; 37/2: 327-340.
18. Zheng B, Ohkawa S, Li H, Roberts-Wilson TK, Price SR. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J 2010; 24: 2660-2669.
19. Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 2004; 279/34: 35298-35305.
20. Gual P, Gremeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF. MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Diabetologia 2003; 46/11: 1532-1542.
21. Mayo-Smith W, Hayes CW, Biller BM, Klibanski A, Rosenthal H, Rosenthal DI. Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 1989; 170/2: 515-518.